211
Views
0
CrossRef citations to date
0
Altmetric
Retina

Optical quality assessment in branch retinal vein occlusion after monthly intravitreal ranibizumab injection: a prospective, case-control study

, , , , , , & ORCID Icon show all
Pages 1005-1011 | Received 07 Jul 2019, Accepted 19 Dec 2019, Published online: 29 Dec 2019

References

  • Diaz-Douton F, Benito A, Pujol J, Arjona M, Guell JL, Artal P. Comparison of the retinal image quality with a Hartmann-Shack wavefront sensor and a double-pass instrument. Invest Ophthalmol Vis Sci. 2006;47:1710–16. doi:10.1167/iovs.05-1049.
  • Artal P, Benito A, Perez GM, Alcon E, De Casas A, Pujol J, Marin JM. An objective scatter index based on double-pass retinal images of a point source to classify cataracts. PLoS One. 2011;6:e16823. doi:10.1371/journal.pone.0016823.
  • Ortiz D, Alio JL, Ruiz-Colecha J, Oser U. Grading nuclear cataract opacity by densitometry and objective optical analysis. J Cataract Refract Surg. 2008;34:1345–52. doi:10.1016/j.jcrs.2008.04.022.
  • Kamiya K, Shimizu K, Saito A, Igarashi A, Kobashi H. Comparison of optical quality and intraocular scattering after posterior chamber phakic intraocular lens with and without a central hole (Hole ICL and Conventional ICL) implantation using the double-pass instrument. PLoS One. 2013;8:e66846. doi:10.1371/journal.pone.0066846.
  • Jimenez JR, Ortiz C, Perez-Ocon F, Jimenez R. Optical image quality and visual performance for patients with keratitis. Cornea. 2009;28:783–88. doi:10.1097/ICO.0b013e318196703a.
  • Tutt R, Bradley A, Begley C, Thibos LN. Optical and visual impact of tear break-up in human eyes. Invest Ophthalmol Vis Sci. 2000;41:4117–23.
  • Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133–41. discussion 41-3.
  • Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol. 2010;94:319–23. doi:10.1136/bjo.2007.135913.
  • Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2003;121:1297–302. doi:10.1001/archopht.121.9.1297.
  • Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT Study. Ophthalmology. 2016;123:330–36. doi:10.1016/j.ophtha.2015.09.035.
  • Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, Group RS. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121:209–19. doi:10.1016/j.ophtha.2013.08.038.
  • Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122:538–44. doi:10.1016/j.ophtha.2014.08.031.
  • Thach AB, Yau L, Hoang C, Tuomi L. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology. 2014;121:1059–66. doi:10.1016/j.ophtha.2013.11.022.
  • Moon BG, Cho AR, Kim YN, Kim JG. Predictors of refractory macular edema after branch retinal vein occlusion following intravitreal bevacizumab. Retina. 2018;38:1166–74. doi:10.1097/IAE.0000000000001674.
  • Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. Prog Retin Eye Res. 2014;41:1–25. doi:10.1016/j.preteyeres.2014.04.001.
  • Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, Nguyen HP, Wang JJ, Wong TY. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1094–101 e5. doi:10.1016/j.ophtha.2010.01.058.
  • Hayreh SS, Podhajsky PA, Zimmerman MB. Branch retinal artery occlusion: natural history of visual outcome. Ophthalmology. 2009;116:1188–94 e1-4. doi:10.1016/j.ophtha.2009.01.015.
  • Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med. 2010;363:2135–44. doi:10.1056/NEJMcp1003934.
  • Lee K, Sohn J, Choi JG, Chung SK. Optical quality in central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2014;55:8598–603. doi:10.1167/iovs.14-14679.
  • Cho JH, Bae SH, Kim HK, Shin YJ. Optical quality assessment in patients with macular diseases using optical quality analysis system. J Clin Med. 2019;8(6). doi:10.3390/jcm8060892.
  • Mimouni M, Segev O, Dori D, Geffen N, Flores V, Segal O. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with macular edema secondary to vein occlusion. Am J Ophthalmol. 2017;182:160–67. doi:10.1016/j.ajo.2017.08.005.
  • Babiuch AS, Han M, Conti FF, Wai K, Silva FQ, Singh RP. Association of disorganization of retinal inner layers with visual acuity response to anti-vascular endothelial growth factor therapy for macular edema secondary to retinal vein occlusion. JAMA Ophthalmol. 2019;137:38–46. doi:10.1001/jamaophthalmol.2018.4484.
  • Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Hirayama T, Tamura H, Yamashita H, Minamoto A, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond). 2008;22:42–48. doi:10.1038/sj.eye.6702498.
  • Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–87. doi:10.1056/NEJM199412013312203.
  • Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K. Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion. Br J Ophthalmol. 2011;95:788–92. doi:10.1136/bjo.2010.192468.
  • Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007;27:1004–12. doi:10.1097/IAE.0b013e3180ed458d.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.